FZD9 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
The FZD9 gene (also spelled FZD9 or Frizzled-9) encodes a member of the Frizzled family of receptors, which are essential components of the Wnt signaling pathway. Frizzled-9 is a seven-transmembrane receptor that binds Wnt ligands and activates both canonical (β-catenin-dependent) and non-canonical Wnt pathways. This receptor plays critical roles in neural development, brain patterning, synaptic function, and has been implicated in neurodegenerative diseases.
| Attribute |
Value |
| Gene Symbol |
FZD9 |
| Official Full Name |
Frizzled class receptor 9 |
| Chromosomal Location |
7q11.23 |
| Gene ID |
2865 |
| UniProt ID |
O00107 |
| Protein Class |
Frizzled family GPCR |
FZD9 is located within the Williams-Beuren syndrome (WBS) critical region on chromosome 7q11.23. The gene spans approximately 45 kb and consists of 8 exons. This region is susceptible to hemizygous deletion in Williams syndrome, a neurodevelopmental disorder.
Frizzled-9 is a 585-amino acid protein with the following structural features:
- N-terminal Extracellular Domain: Contains a cysteine-rich domain (CRD) with 10 conserved cysteine residues that bind Wnt ligands
- Seven transmembrane domains: Classic GPCR-like architecture
- C-terminal intracellular tail: Contains PDZ domain-binding motifs for protein interactions
The receptor forms homodimers and can also heterodimerize with other Frizzled proteins, expanding its signaling repertoire.
FZD9 activates multiple downstream signaling cascades:
- Wnt ligand binding to FZD9 extracellular domain
- Recruitment of Dishevelled (DVL) protein
- Inhibition of GSK3β (glycogen synthase kinase 3β)
- Stabilization and nuclear translocation of β-catenin
- TCF/LEF-mediated gene transcription
- Planar Cell Polarity (PCP) pathway: Involves DVL and small GTPases (Rac, Rho)
- Wnt/Ca²⁺ pathway: Activation of PLC and intracellular calcium release
In the human brain, FZD9 is expressed in:
- Cerebral cortex: Particularly during development
- Hippocampus: CA regions and dentate gyrus
- Cerebellum: Purkinje cells and granule cells
- Subventricular zone: Neural stem cell niches
- Olfactory bulb: Neurogenesis regions
- Thalamus and hypothalamus: Various nuclei
During development, FZD9 expression peaks in embryonic and early postnatal stages, with lower but detectable expression in adult brain.
FZD9 plays essential roles in:
- Neural tube patterning: Anterior-posterior and dorsal-ventral patterning
- Cortical neurogenesis: Regulation of neural progenitor proliferation
- Neuronal migration: Guidance of migrating neurons
- Synapse formation: Pre- and post-synaptic differentiation
- Axon guidance: Pathfinding of developing axons
In mature neurons, FZD9 contributes to:
- Long-term potentiation (LTP) and long-term depression (LTD)
- Spine morphogenesis
- Synaptic protein recruitment
- Dendritic arborization
The receptor continues to function in the adult brain:
- Regulation of neural stem cell proliferation
- Olfactory bulb neurogenesis
- Hippocampal dentate gyrus maintenance
FZD9 lies within the Williams syndrome critical region. Hemizygous deletion of this region (including FZD9) contributes to:
- Characteristic facial features
- Cardiovascular problems (supravalvular aortic stenosis)
- Hyperacusis (sound sensitivity)
- Neurodevelopmental differences including:
- Relative strength in language but challenges with visuospatial cognition
- Gregarious personality phenotype
The role of FZD9 haploinsufficiency in these phenotypes is an active area of research.
Alzheimer's Disease (AD):
- Wnt signaling is dysregulated in AD brains
- Amyloid-β interferes with FZD9-mediated signaling
- Loss of Wnt/Frizzled signaling promotes tau pathology
- FZD9 as potential therapeutic target for cognitive decline
Parkinson's Disease (PD):
- Wnt pathway genes show altered expression in PD brains
- FZD9 may interact with α-synuclein pathology
- Dopaminergic neuron survival requires Wnt signaling
Amyotrophic Lateral Sclerosis (ALS):
- Wnt pathway alterations in motor neuron disease
- FZD9 potentially involved in motor neuron survival
FZD9 functions as a tumor suppressor in certain contexts:
- Loss of FZD9 expression in some malignancies
- Wnt dysregulation contributes to uncontrolled proliferation
FZD9 interacts with numerous proteins:
¶ Wnt Ligands
- Wnt1, Wnt3, Wnt3a (canonical activators)
- Wnt5a, Wnt11 (non-canonical)
- Dishevelled (DVL1, DVL2, DVL3)
- Axin
- GSK3β
- β-catenin
- Porcupine (POSTN)
- Wntless (WLS)
- LRP5/LRP6 (for canonical signaling)
- RYK (alternative receptor)
- Ror1/Ror2 (non-canonical)
Several SNPs in FZD9 have been associated with:
- rs3812111: Associated with cognitive function
- rs17259997: In promoter region, may affect expression
- rs10235097: Linked to psychiatric phenotypes
While FZD9 is not a major disease-causing gene, variants may modify:
- Neurodevelopmental disorder severity
- Neurodegenerative disease progression
- Cancer susceptibility
- Knockout mice: Fzd9-null mice show subtle phenotypes
- Conditional knockouts: Brain-specific deletions
- Zebrafish models: For developmental studies
- In vitro systems: HEK293, neuronal cultures
- Wnt agonists: Wnt3a, SB-21687 (small molecule)
- Wnt antagonists: Dkk1, sFRPs (soluble Frizzled-related proteins)
- Antibodies: For receptor localization studies
FZD9 and the Wnt pathway offer therapeutic opportunities:
| Approach |
Target |
Status |
| Wnt agonists |
FZD9 activation |
Preclinical |
| Wnt antagonists |
FZD9 inhibition |
Cancer trials |
| Small molecule modulators |
FZD9/LRP complex |
Research |
Potential applications include:
- Cognitive enhancement in AD
- Neuroprotection in PD
- Neural regeneration after injury
FZD9 encodes a critical Wnt receptor with diverse functions in brain development and maintenance. While not a primary disease gene, its position in the Williams syndrome critical region and roles in neurodegenerative processes make it an important gene to understand. The Wnt/Frizzled pathway remains a promising therapeutic target for neurological disorders.